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Abstract. The use of culture and a nested polymerase chain reaction (PCR) of blood in predicting the probability of
relapse was evaluated in 20 patients co-infected with Leishmania and human immunodeficiency virus (HIV). Fourteen
of 20 patients relapsed, with 24 clinical relapses diagnosed. During clinical relapse, the parasite was detected by culture
in 21 of 24 blood samples and by nested PCR in 23 of 24 blood samples. After treatment and during asymptomatic
periods, the parasite was detected by culture in 18 (19.1%) of 94 blood samples and by nested PCR in 58 (61.7%) of 94
blood samples. For positive blood cultures, the Kaplan-Meier probability estimates for relapse at 6, 12, 18, and 24 months
were 44%, 68%, 76%, and 76%, respectively, while for positive nested PCRs, the estimates were 20%, 33%, 45%, and
50%, respectively. For negative blood cultures, relapse probabilities for the same time points were 7%, 12%, 12%, and
12%, while for negative nested PCRs, these probabilities were 8%, 14%, 21%, and 26%. Nested PCR-positive results
in asymptomatic periods indicated presence of the parasite, but not necessarily relapse. However, the presence of viable
parasites during post-treatment follow-up increased the probability of relapse and showed that culture positivity could
be a good relapse marker.
INTRODUCTION
Visceral leishmaniasis (VL), which is caused by Leishmania
infantum, is endemic throughout the Mediterranean basin. It
is a frequent opportunistic disease in patients infected with
human immunodeficiency virus (HIV) in southern Europe,
where 25–70% of adult patients with VL are co-infected with
HIV, and it is estimated that 1.5–9% of patients with acquired
immunodeficiency syndrome (AIDS) will develop leishma-
niasis.1
Relapse of VL is an early event, occurring in most HIV-
Leishmania co-infected patients during the first year after
treatment of VL.2,3 It does not depend on the clinical features
of the leishmanial infection, the degree of immunosuppres-
sion, or the presence of AIDS. Despite the use of highly
active anti-retroviral therapy, high VL relapse rates (26–70%)
have been observed in co-infected patients.4,5 Clinical moni-
toring does not provide sufficient information to predict re-
lapse because most patients are asymptomatic during the
post-treatment period and develop symptoms only weeks be-
fore relapse.
The aim of the present study was to evaluate two diagnostic
methods, culture and nested-polymerase chain reaction
(PCR), in blood samples of co-infected patients to establish
the value of these techniques as potential relapse markers.
MATERIALS AND METHODS
Patients. A prospective study was conducted in Barcelona,
Spain from June 1998 to June 2001. Included in this study
were 20 HIV-infected patients with VL at two different hos-
pitals. All patients gave signed, informed consent for partici-
pation in this study. The study was reviewed and approved by
the ethics committees of each center. Diagnosis of VL was
based in each case on an evaluation of the symptoms and
signs associated with VL, including intermittent fever, hepa-
toesplenomegaly, pancytopenia and anemia, and identifica-
tion of Leishmania amastigotes by direct examination or/and
by culture in bone marrow. The patients received one of the
following treatments at standard doses: meglumine antimoni-
ate, 20 mg of pentavalent antimony/kg/day for 28 days, or
amphotericin B lipidic complex, 3 mg/kg/day for 10 days. Af-
ter clinical recovery, all patients were monitored. The treat-
ment was considered successful when patients showed clinical
recovery and no parasites were detected in bone marrow one
month after completion of therapy. The diagnosis of clinical
relapse or therapeutic failure was confirmed by direct exami-
nation or/and culture of bone marrow.
Samples and methods. Nine milliliters of peripheral blood
obtained by sterile venipuncture and collected into tubes con-
taining EDTA for in vitro cultivation and nested PCR were
collected at monthly intervals during post-treatment follow-
up and, in patients who relapsed, upon diagnosis of relapse.
Peripheral blood mononuclear cells (PBMCs) were isolated
from blood by the Ficoll-Paque™ Plus procedure (Amersham
Pharmacia Biotech, Piscataway, NJ). Preparations were di-
vided into two aliquots, one used immediately for culture and
the other stored at −40°C for nested PCR.
The PBMC samples were seeded into Schneider’s insect
culture medium (Sigma, St. Louis, MO) spplemented with
20% heat-inactivated fetal calf serum, 1% sterile human
urine, and gentamicin (25 g/mL) (Sigma). Cultures were
maintained at 24–26°C, examined by inverted microscopy
twice a week, and sub-cultured every 2 weeks for 6 months
before being pronounced negative.
Nested PCR amplification was performed on PBMCs ac-
cording to a standard technique.6 DNA was extracted from
0.2 mL of PBMCs adjusted to a concentration of 1 × 106
PBMCs/mL with the High Pure PCR Template Preparation
Kit (Roche Molecular Biochemicals, Mannheim, Germany),
according to the manufacturer’s instruction. External primers
Ext (5-AAT TCG ACG ATC ACG AGG TC-3) and E2b
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(5-CGA CTC GGT TGG CAC ACT GC-3) and internal
primers P-1 (5-ACG AGG TCA GCT CCA CTC C-3) and
P-2 (5-CTG CAA CGC CTG TGT CTA CG-3) were used.
The PCR mixture contained 5 L of DNA, 1× PCR buffer (10
mM Tris-HCl, pH 8.3, 50 mM KCl, and 0.01% gelatin), 1.5
mM MgCl2, 0.1 mM of each deoxynucleotide tryphosphate,
0.2 M of each primer to include Ext/E2b (Amersham Phar-
macia Biotech), and 0.5 units of RedTaq polymerase (Sigma)
in a final volume of 20 L. Reactions were cycled in a PTC-
200 thermocycler (MJ Research, Waltham, MA) using the
following conditions: 96°C for 5 minutes; 30 cycles at 94°C for
30 seconds, 59°C for 30 seconds, and 72°C for 30 seconds; and
72°C for 5 minutes. The second-round amplification con-
tained 2 L of the first-round amplification product as the
template and primers for P-1 and P-2. Reactions were visu-
alized by electrophoresis on a 3% agarose gel. Samples were
positive when a product of 100 basepairs was detected.
Statistical analysis. The Kaplan-Meier method was used in
survival analysis, and curves for the two groups (positive ver-
sus negative by culture, and positive versus negative by nested
PCR) were compared by the Mantel-Cox log-rank and
Breslow tests (SPSS Inc., Chicago, IL).
RESULTS
During the study period, the efficacy of specific drug treat-
ment was monitored by blood samples over a period of one
month to three years. Fourteen of the 20 patients exhibited
clinical relapse, with 24 clinical relapses diagnosed. Nine pa-
tients had a single relapse, two had two, one had three, and
two had four. The remaining six patients remained free of
new episodes throughout the study period.
A total of 118 peripheral blood samples were collected and
analyzed simultaneously by culture and nested PCR. These
two methods gave concordant results in 72 cases, 37 of which
were positive and 35 negative. In two instances, culture was
positive and nested PCR negative; one of these cases was a
relapse. In 43 instances, PBMC culture was negative and
nested PCR positive; three of the cases were relapses. At time
of clinical relapse, the parasite was detected in blood by cul-
ture in 21 of 24 samples and by nested PCR in 23 of 24
samples. During the post-treatment monitoring, and in ab-
sence of clinical symptoms, the parasite was detected by cul-
ture in 18 (19.1%) of 94 samples and by nested PCR in 58
(61.7%) of 94 samples, with corresponding negative predic-
tive values of 80.8% (76 of 94) and 38.2% (36 of 94), respec-
tively (Table 1).
Kaplan-Meier estimates of the probability of relapse at 6,
12, 18, and 24 months were 8% (95% confidence interval [CI]
 0–14%), 14% (95% CI  5–22%), 21% (95% CI  10–
33%), and 26% (95% CI  12–39%), respectively, in those
patients with a negative blood culture. However, in those
patients with a positive culture, relapse probabilities were
44% (95% CI  22–67%), 68% (95% CI  46–89%), 76%
(95% CI  54–97%), and 76% (95% CI  54–97%), respec-
tively (Figure 1). There were significant differences in the
probability of relapse between patients with negative and
positive blood cultures (P < 0.001).
Kaplan-Meier estimates of the probability of relapse at 6,
12, 18, and 24 months were 7% (95% CI  0–16%), 12%
(95% CI  0–24%), 12% (95% CI  0–24%), and 12%
(95% CI  0–24%), respectively, in patients with negative
nested PCR results, and 20% (95% CI  10–31%), 33%
(95% CI  20–46%), 45% (95% CI  30–60%), and 50%
(95% CI  33–67%), respectively, in those patients with posi-
tive nested PCR results (Figure 2). Differences in the prob-
ability of relapse between patients with negative nested PCR
results and patients with positive nested PCR results were
significant (P < 0.001).
DISCUSSION
The high percentage of relapses in co-infected patients fol-
lowing treatment1–3 highlights the need not only for post-
treatment parasite control, but also for alternative diagnostic
techniques that use non-invasive samples. Peripheral blood
has the advantage over such conventional samples as bone
marrow or lymph aspirate in ease of collection and being a
relatively simple and non-invasive procedure. Blood culture
and/or PCR in VL diagnosis has been used extensively and
shows a range of sensitivities depending on the study: 55–88%
for culture7–10 and 82–98% for PCR.9,11–16 Our results show
that culture and the nested PCR showed high sensitivity dur-
ing clinical episodes, when parasitemia is generally higher
(87.5% and 95.8%, respectively).
Post-treatment monitoring of parasitemia during asymp-
tomatic periods showed markedly different sensitivities be-
TABLE 1
Results of blood cultures and nested-polymerase chain reactions
(PCRs) obtained during post-treatment in 20 patients with human
immunodeficiency virus–Leishmania co-infection during both clini-
cal relapse and asymptomatic periods





TotalCulture+ Culture− Total Culture+ Culture− Total
PCR+ 20 3 23 17 41 58 81
PCR− 1 0 1 1 35 36 37
Total 21 3 24 18 76 94 118
* Negative predictive value of culture  80.8% (76 of 94); negative predictive value of
nested PCR  38.2% (36 of 94).
FIGURE 1. Kaplan-Meier probability estimates for relapse in pa-
tients co-infected with Leishmania and human immunodeficiency vi-
rus during post-treatment monitoring based on blood culture results.
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tween the two diagnostic methods used in this study. Al-
though Leishmania DNA was detected in 58 (61.7%) of 94
blood samples, only 17 were associated with the presence of
parasites in blood culture. No association between positive
results and clinical relapse during asymptomatic periods was
observed. These differences were observed by Lachaud and
others,9 as well as in a preliminary study done for the work
presented here.15 Low parasitic loads, which are likely
present after treatment and during asymptomatic periods,
could be the principle cause of low culture sensitivity, and
may explain the high sensitivity of the nested PCR in detect-
ing infections, even when levels of circulating parasites are
low. However, inoculum size affects the growth of Leishma-
nia; cultures initiated with low inoculums failed to promote
cell growth.17 Recent studies on blood donors in disease-
endemic areas as southern France and Spain reported low
blood culture sensitivity, versus PCR, when parasitemia was
low.18,19
Multivariate proportional hazard analyses showed that
positive result in the nested PCR was not always associated
with clinical disease and that at 24 months post-treatment the
probability of relapse was 50%. These data differ from those
of another group who reported positive PCR results predic-
tive of clinical relapse.20 Most likely, the use of a nested PCR
procedure, compared with a conventional PCR, resulted in an
increase in overall sensitivity, but with a decrease in the nega-
tive predictive value with respect to the culture (38.2% versus
80.8%). However, when the culture was positive, risk of re-
lapse increased to 76%. These results suggest that positive
PBMC cultures, in relation to greater parasitic loads, are as-
sociated with higher risks for a new clinical episode, thereby
corroborating the data of Bossolasco and others,21 who re-
ported that clinical relapse was preceded by a substantial in-
crease in blood parasite levels, as quantified by real-time
PCR. However, during follow-up, the risk of relapse in pa-
tients with a negative nested PCR result was low (12%),
whereas patients with a negative blood culture had a two-fold
risk of relapse (26%).
In conclusion, nested PCR is an appropriate technique for
monitoring long-term efficacy of treatment. A negative result
is strongly indicative of successful control of the infection and
efficacy of treatment, whereas a positive nested PCR result
during an asymptomatic period is indicative of the presence of
the parasite, but not necessarily of relapse. In contrast, the
probability of relapse when a blood culture is positive is sig-
nificantly higher than when a nested PCR result is positive.
The presence of viable parasites during post-treatment fol-
low-up increases the likelihood of relapse, demonstrating that
a positive culture could be a good relapse marker.
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